Omnicell (NASDAQ:OMCL) Downgraded to Hold Rating by StockNews.com

StockNews.com cut shares of Omnicell (NASDAQ:OMCL - Free Report) from a buy rating to a hold rating in a research report released on Monday.

A number of other analysts also recently issued reports on the company. Benchmark reaffirmed a "buy" rating and issued a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Wells Fargo & Company decreased their price objective on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Bank of America reduced their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $51.00.

Omnicell Trading Down 0.7 %

Shares of NASDAQ OMCL traded down $0.23 during midday trading on Monday, reaching $35.12. 515,484 shares of the stock were exchanged, compared to its average volume of 517,512. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.75. The business has a 50-day simple moving average of $39.16 and a two-hundred day simple moving average of $42.64. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 130.06, a P/E/G ratio of 7.53 and a beta of 0.85.

Remove Ads

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities research analysts expect that Omnicell will post 1.09 EPS for the current year.

Hedge Funds Weigh In On Omnicell

Several hedge funds and other institutional investors have recently modified their holdings of OMCL. Smartleaf Asset Management LLC lifted its holdings in shares of Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares in the last quarter. Johnson Financial Group Inc. purchased a new position in shares of Omnicell during the 4th quarter valued at $37,000. Van ECK Associates Corp increased its stake in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Omnicell in the fourth quarter valued at about $53,000. Finally, First Horizon Advisors Inc. grew its position in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after purchasing an additional 355 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.